NCT02019420View on ClinicalTrials.gov

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

PHASE3CompletedINTERVENTIONAL

Enrollment

726

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

June 22, 2018

Study Completion Date

June 22, 2018

Conditions

Pneumonia

Interventions

DRUG

Tedizolid phosphate

Tedizolid phosphate IV 200 mg once daily

DRUG

Linezolid

Linezolid IV 600 mg twice daily

All Listed Sponsors

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02019420 - Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) | Biotech Hunter | Biotech Hunter